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Dear Editor,
Hardly any topic in modern critical
care medicine remains as controversial as steroid administration in acute
respiratory distress syndrome
(ARDS), despite multiple adult randomized controlled trials (RCTs) and
recent pediatric data. The article by
Yehya et al. [1] and the editorial
commentary by Peters et al. [2] are
vital, since few, if any, therapeutic
approaches are simultaneously associated with such profound potential
benefits and risks as steroid therapy in
critically ill patients.
Marked contradiction, however,
exists between the Yehya et al. data
and the findings of well-designed and
protocol-driven RCTs in adult ARDS
patients. These studies consistently
reported significant improvements in
markers of systemic inflammation,
ventilator-free days, ICU-free days,
no changes or actually improved
survival, and either no increase or
decreases in infection rate [3, 4]. The
findings of Yehya et al. cannot be
interpreted because the specific indications for corticosteroid use were not
reported. To imply that any type of
steroid, at any concentration, and
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used for more than 24 h represents a
protocol-driven treatment for pediatric ARDS (PARDS) is simply not
justifiable.
Further, grouping short-term (less
than 24 h) and non-corticosteroid
exposed patients together is an
improper control for evaluating steroid therapy. Corticosteroids can exert
important, non-genomic effects
within minutes, including decreased
cell adhesion, phosphokinase activation, MCP-1 and H2O2 release, CD63
translocation, TNF-a and IL-6
expression. Possible corticosteroid
effects cannot be assessed unless
exposed and non-exposed patients are
categorically separated. Thus,
proposing that this single-center,
observational study ‘‘has relevance
for clinical practice’’, a conclusion
unsupported by data, will likely mislead and confound many bedside
physicians. Undoubtedly, the most
likely explanation for Yehya et al.’s
findings are (1) selection of steroid
therapy for the sickest patients (confounding by indication) and (2)
rebound effects resulting from abrupt
discontinuation of corticosteroids, as
is well documented by worsening
PaO2/FiO2 ratios and increasing CRP
levels.
Owing to the wide-ranging implications and inherent responsibility of
publishing patient data, it is imperative that we treat this topic with the
utmost equipoise until clear evidence
for or against steroid use in ARDS/
PARDS is gained. Whether comparative effectiveness research (CER)
can provide such evidence is questionable, since the US Food and Drug
Administration, European Medicines
Agency, or other labeling agencies do
not consider this research methodology Level 1 evidence. CER studies
can ‘‘adjust’’ the outcomes for

measured confounders, and bootstrapping techniques like propensity
scoring can reduce the margin of
inferential errors, but only large, welldesigned RCTs can control for
unmeasured and non-measurable
confounders. We recommend caution
in drawing conclusions from a data
set with multiple confounding variables and improper controls.
Statistical approaches such as
propensity score matching can only
take into account measured confounding factors, whereas
randomized trials allow for controlling of both measured and
unmeasured confounders. The beneficial or no-harm results reported in
adult RCTs cannot be disregarded
unless systematically investigated in
pediatric patients. We recently published a feasibility RCT investigating
prolonged low-dose methylprednisolone in pediatric ARDS [5] and,
undoubtedly, there is an urgent need
to conduct a large-scale, well-designed RCT in PARDS.
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